SMMT vs. ARQT

In the year-to-date period, SMMT achieves a 584.67% return, which is significantly higher than ARQT's 364.09% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Summit Therapeutics Inc. (SMMT) and Arcutis Biotherapeutics, Inc. (ARQT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current SMMT Sharpe Ratio is 2.14, which is lower than the ARQT Sharpe Ratio of 5.57. The chart below compares the historical Sharpe Ratios of SMMT and ARQT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither SMMT nor ARQT has paid dividends to shareholders.

The maximum SMMT drawdown since its inception was -95.75%, roughly equal to the maximum ARQT drawdown of -95.02%. Use the drawdown chart below to compare losses from any high point for SMMT and ARQT. For additional features, visit the drawdowns tool.

The current volatility for Summit Therapeutics Inc. (SMMT) is 17.79%, while Arcutis Biotherapeutics, Inc. (ARQT) has a volatility of 23.51%. This indicates that SMMT experiences smaller price fluctuations and is considered to be less risky than ARQT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Summit Therapeutics Inc. and Arcutis Biotherapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.